Image from breakthrought1d.org: Breakthrough T1D Researchers Present Latest Findings at Major Diabetes Conference

breakthrought1d.org (via breakthrought1d.org) / Source publication — credited and linked

Cure & Advancements/June 17, 2025/2 min read

Breakthrough T1D Researchers Present Latest Findings at Major Diabetes Conference

Over 100 studies on cell therapies, disease-modifying treatments, and diabetes technology will be shared at the ADA's 85th Scientific Sessions in Chicago this June. Breakthrough T1D-funded researchers will showcase progress toward better prevention and treatment options for Type 1 diabetes.

News report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

The ADA's 85th Scientific Sessions (June 20–23, 2025) brings together over 11,000 scientists, healthcare professionals, and industry leaders to share diabetes research breakthroughs.
Breakthrough T1D-funded researchers will present over 100 studies covering cell therapies, disease-modifying therapies, diabetes technology, and new treatments.
Key presentations include updates on manufactured islet scaling by Jeffrey Millman, Ph.D., and results from the BANDIT study on baricitinib's ability to preserve insulin production.
The Beta Cell Replacement Consortium will provide updates on cell therapy research as part of ongoing efforts to develop new therapeutic approaches.

A Global Gathering for Diabetes Research

From June 20–23, 2025, Chicago will host the American Diabetes Association's 85th Scientific Sessions—the largest annual diabetes conference in the world. Over 11,000 attendees, including researchers, clinicians, and industry leaders, will convene to share and discuss the latest advancements in Type 1 diabetes research, prevention, and care.

Breakthrough T1D, a leading nonprofit funder of Type 1 diabetes research, will be present at the conference to highlight work supported by its grants. Each year, the organization's funded researchers present their latest findings, demonstrating incremental progress toward improved treatments and prevention strategies.

Over 100 Studies Spanning Multiple Research Areas

This year's sessions will feature presentations on over 100 studies across several research domains: cell therapies, disease-modifying therapies, diabetes technology, and novel treatments. This breadth reflects the multiple pathways scientists are exploring to address Type 1 diabetes.

Cell Therapy and Insulin-Preserving Research Highlights

Breakthrough T1D-funded researchers from the Beta Cell Replacement Consortium will present updates on cell therapy research. Jeffrey Millman, Ph.D., will discuss work on scaling up and optimizing manufactured islets—an important step toward making cell-based approaches more practical.

Additionally, research on disease-modifying therapies will be featured. Professor Thomas Kay, MBBS, Ph.D., will provide an update on findings from the phase 2 BANDIT study, which Breakthrough T1D funded. The trial examined baricitinib, a JAK inhibitor, and found that it can help preserve insulin production, as measured by C-peptide levels.

Evidence label

Origin: breakthrought1d.org (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.